Bristol-myers Squibb Company · NYSE:BMY
Bristol-myers Squibb — Shareholder Meeting (April 2025)
14 slides from Bristol-myers Squibb's shareholder meeting presentation, Apr 15, 2025
Slide 1: Proxy Season Update April 2025
Proxy Season Update April 2025
Slide 2: Our Mission, Vision and Values
2 Our Mission To discover, develop and deliver innovative medicines that help patients prevail over serious diseases Our Vision To be the world's leading biopharma company that transforms patients' lives through science Our Values • Integrity • Innovation • Urgency • Passion • Accountability • Inclu
Slide 3: Reshaping BMS for sustained top-tier growth: Continued Pipeline Progress
Reshaping BMS to achieve sustained top-tier growth by the end of the decade, maximize long-term shareholder value and accelerate our ability to deliver breakthrough medicines to even more patients faster 3 Continued Pipeline Progress 23 Approvals from the FDA and other markets 20 Submissions to the
Slide 4: Delivering sustainable Growth & Innovation in 2024
Delivering sustainable Growth & Innovation in 2024 4 * Growth Portfolio includes: & other Growth Products, including Onureg® (azacitidine), Inrebic® (fedratinib), Empliciti® (elotuzumab), and Nulojix® (belatacept), and royalty revenue. ** Legacy Portfolio includes Eliquis® (apixaban), Revlimid® (len
Slide 5: Committed to Sound Corporate Governance
Committed to Sound Corporate Governance 5 Board Accountability & Shareholder Rights Regular shareholder engagement Limit on total board memberships for sitting CEO (2) Annual election of Directors Proxy access shareholder right Majority voting standard for election of Directors Ability t
Slide 6: Board of Directors nominees
Christopher S. Boerner, Ph.D. Theodore R. Samuels Peter J. Arduini Deepak L. Bhatt, M.D., M.P.H., M.B.A. Julia A. Haller, M.D. Manuel Hidalgo Medina, M.D., Ph.D. Board Chair & Chief Executive Officer of the Company Lead Independent Director (C) (C) (C) More than 20 years of experience in the biotech
Slide 7: Our Board Nominees Have a Comprehensive Collection of Varied Backgrounds
Leadership Strategic Thinking Sound Business Judgment Integrity & Ethics Our Board Nominees Have a Comprehensive Collection of Varied Backgrounds, Industry Experiences & Personal Characteristics 7 Healthcare Experience in relevant areas within the healthcare industry, including science, manufacturin
Slide 8: Executive Compensation Supporting our Core Strategy
Executive Compensation Supporting our Core Strategy 8 2024 CEO Target Pay Mix CEO target compensation approximated the 35th percentile of our primary peer and PHRA Survey peer groups. 91% 78% of target pay is performance-based and at risk of target pay delivered in long-term equity Incentives with t
Slide 9: 2024 Executive Compensation Program
2024 Executive Compensation Program:Supporting Revenue Renewal and Execution of Our Core Strategy1 9 Base Salary Allows us to attract and retain talent in a highly competitive labor market Based on specialized qualifications, experience and role impact, pay levels of comparable positions within peer
Slide 10: Executive Compensation Governance Practices
Executive Compensation Governance Practices 10 What We Do: What We Don’t Do: 100% performance-based annual and long-term incentives X No guaranteed incentives with our Named Executive Officers Caps on the payouts under our annual and long-term incentive award programs X Prohibition on speculativ
Slide 11: 2025 Bristol Myers Squibb Board recommendations
11 2025 Bristol Myers Squibb Board recommendations: Management Proposals Shareholder Proposals FOR Election of Directors AGAINST Shareholder Proposal on Corporate Financial Sustainability FOR Advisory Vote to Approve the Compensation of our Named Executive Officers AGAINST Shareholder Proposal on a
Slide 12: Board unanimously recommends a vote AGAINST shareholder proposals
12 Accordingly, the Board of Directors unanimously recommends a vote “AGAINST” these shareholder proposals. Shareholder Proposal on Corporate Financial Sustainability Shareholder Proposal on a Request to Cease DEI Efforts The Board has carefully considered this proposal and believes the actions requ
Slide 13: Forward-looking statements
13 This presentation (as well as the oral statements made with respect to information contained in this presentation) contains statements about Bristol-Myers Squibb Company’s (the “Company”) future financial results, plans, business development strategy, anticipated clinical trials, results and regu
Slide 14: Bristol Myers Squibb
(lh Bristol Myers Squibb’
Bristol Myers Squibb — Shareholder Meeting (April 2025) on 6ix